Fulgent Genetics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Fulgent Genetics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • Fulgent Genetics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$18.9M, a 4.51% increase year-over-year.
  • Fulgent Genetics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$192M, a 137% decline year-over-year.
  • Fulgent Genetics, Inc. annual Operating Income (Loss) for 2023 was -$196M, a 210% decline from 2022.
  • Fulgent Genetics, Inc. annual Operating Income (Loss) for 2022 was $179M, a 73.6% decline from 2021.
  • Fulgent Genetics, Inc. annual Operating Income (Loss) for 2021 was $676M, a 133% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$192M -$18.9M +$892K +4.51% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 -$193M -$21.8M +$3.03M +12.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-03
Q4 2023 -$196M -$151M -$115M -313% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$81M $214K -$138K -39.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-03
Q2 2023 -$80.8M -$19.8M -$32.6M -255% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 -$48.2M -$24.8M -$227M -112% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q4 2022 $179M -$36.6M -$187M -124% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-28
Q3 2022 $366M $352K -$159M -99.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $525M $12.8M -$86.1M -87.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 $611M $202M -$65M -24.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 $676M $151M -$75M -33.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $751M $159M +$95.8M +151% Jul 1, 2021 Sep 30, 2021 10-K 2023-02-28
Q2 2021 $655M $98.9M +$96.3M +3646% Apr 1, 2021 Jun 30, 2021 10-K 2023-02-28
Q1 2021 $559M $267M +$269M Jan 1, 2021 Mar 31, 2021 10-K 2023-02-28
Q4 2020 $290M $226M +$226M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 $63.8M $63.5M +$62M +4110% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-28
Q2 2020 $1.83M $2.64M +$2.35M +795% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-28
Q1 2020 -$519K -$1.91M -$91K -4.99% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-28
Q4 2019 -$428K -$409K +$620K +60.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 -$1.05M $1.51M +$2.36M Jul 1, 2019 Sep 30, 2019 10-K 2021-03-08
Q2 2019 -$3.4M $295K +$1.3M Apr 1, 2019 Jun 30, 2019 10-K 2021-03-08
Q1 2019 -$4.7M -$1.82M +$371K +16.9% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-08
Q4 2018 -$5.07M -$1.03M +$1.04M +50.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$6.11M -$846K +$635K +42.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-13
Q2 2018 -$6.75M -$1M -$851K -567% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-13
Q1 2018 -$5.9M -$2.19M -$2.41M -1102% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-13
Q4 2017 -$3.48M -$2.07M -$3.33M -264% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-22
Q3 2017 -$153K -$1.48M -$786K -113% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-22
Q2 2017 $633K -$150K -$1.12M -115% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-22
Q1 2017 $1.75M $219K +$834K Jan 1, 2017 Mar 31, 2017 10-K 2019-03-22
Q4 2016 $919K $1.26M +$8.6M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-20
Q3 2016 -$7.68M -$695K -$1.88M -159% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-20
Q2 2016 -$5.81M $970K +$223K +29.9% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-20
Q1 2016 -$6.03M -$615K -$1.02M -252% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-20
Q4 2015 -$5.01M -$7.34M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-17
Q3 2015 $1.18M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-17
Q2 2015 $747K Apr 1, 2015 Jun 30, 2015 10-K 2017-03-17
Q1 2015 $405K Jan 1, 2015 Mar 31, 2015 10-K 2017-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.